Clavulanic Acid Veterinary Grade API is supplied as potassium clavulanate, CAS 61177-45-5, corresponding to the free acid CAS 58001-44-8. The molecular formula is C₈H₈KNO₅, with relative molecular mass 237.25 g/mol; the free acid C₈H₉NO₅ has relative molecular mass 199.16 g/mol. The material is a white-to-off-white hygroscopic crystalline powder supplied in two physical grades: a non-sterile oral grade for tablets, capsules, oral powders, granules, and feed premixes, and a sterile grade for powder-for-injection. Supplier model identification is manufacturer-specific but usually encodes the physical grade and particle size range; typical designations distinguish oral direct-compression grade from oral premix grade. Clavulanic acid itself has no clinically relevant direct antibacterial activity; it is a progressive inhibitor of serine beta-lactamases and is combined with amoxicillin trihydrate at veterinary ratios of 4:1 or 7:1 amoxicillin to clavulanic acid. Release testing follows the current Ph. Eur. and USP-NF monographs for potassium clavulanate. High-performance liquid chromatography is conducted according to USP 621 and Ph. Eur. 2.2.29; water is determined by Karl Fischer titration according to Ph. Eur. 2.5.12; residual solvents are controlled according to Ph. Eur. 2.4.24 and VICH GL18. Veterinary-specific impurity limits follow VICH GL11. The API differs from amoxicillin monotherapy because it restores activity against beta-lactamase-producing isolates but does not broaden the spectrum against Pseudomonas aeruginosa or methicillin-resistant staphylococci.

What Limits Aqueous Stability in Reconstituted Oral and Injectable Products?

Solution stability of potassium clavulanate is controlled primarily by pH, temperature, and buffer composition. Maximum stability of the free acid occurs near pH 5.5 to 6.0; at pH above 8.0 and below 4.5, beta-lactam ring opening accelerates and clavulanate content declines rapidly. Published first-order kinetic data for the isolated API in aqueous media are limited to model systems, but the manufacturing consequence is clear: aqueous granulation, aqueous film-coating, and ready-to-use aqueous liquids are avoided for clavulanate-containing veterinary products. Oral suspensions are manufactured as dry powders and reconstituted before dispensing; refrigerated shelf life is product-specific and commonly set at 7 days at 2–8°C. At 25°C, an unprotected reconstituted suspension may lose potency within 24 h; therefore ambient temperature exposure during dosing should be minimized. For injectable products, lyophilized or dry-mixed powder is filled into Type I glass vials under low-humidity conditions. Residual moisture is controlled to ≤ 1.5% w/w by Karl Fischer titration per Ph. Eur. 2.5.12, and stopper moisture is controlled because headspace water accelerates degradation. Reconstitution with Water for Injection typically produces a solution pH of 5.5–8.0. Alkaline diluents such as sodium bicarbonate injection and low-pH dextrose vehicle reduce clavulanate recovery; sodium chloride 9 mg/mL is preferred for intravenous dilution unless the finished product label specifies otherwise. If reconstituted solution must be held before administration, it should be refrigerated and used within the product-specific compatibility window, because aqueous degradation is not negligible even at 4°C. On sterile powder filling lines, environmental relative humidity below 30% and nitrogen flushing reduce water uptake and maintain powder flow.

Tablet and capsule manufacture of amoxicillin/clavulanate combinations favours dry processing to avoid exposing clavulanate potassium to water. Direct compression of a blend containing amoxicillin trihydrate, potassium clavulanate, microcrystalline cellulose, crospovidone, and magnesium stearate is performed on rotary tablet presses with compression force 15–25 kN for round tooling in the 12–20 mm diameter range; tablet hardness is maintained at 60–120 N to meet friability requirements per USP 1216 and Ph. Eur. 2.9.7. Roller compaction is used when granulation is needed for flow or content uniformity. On production-scale roller compactors with roll force 15–30 kN/cm, the resulting granules are screen-milled; this dry method avoids the hydrolytic degradation risk of aqueous granulation. Capsule filling of dry powders requires relative humidity below 40% because the capsule shell can transfer moisture to the hygroscopic API; sealed packaging with desiccant is used after filling.

Granules and oral powders are prepared by low-shear mixing with sucrose, sorbitol, or lactose carriers followed by non-aqueous granulation using anhydrous isopropanol and a polyvinylpyrrolidone binder. The wet mass is dried in a fluid-bed dryer with inlet air temperature not exceeding 30°C; residual moisture is held at ≤ 1.5% w/w before packaging in foil-lined unit-dose containers. Suspending agents such as xanthan gum at 0.2–0.5% w/w and colloidal silicon dioxide are incorporated in the dry blend to control sedimentation after reconstitution. Premixes for medicated feed are produced by blending oral-grade API with a calcium carbonate or lactose carrier in a horizontal ribbon mixer at 20–40 rpm for 15–20 min. The carrier particle size distribution is matched to the API to limit segregation, and the finished premix should have a mixing coefficient of variation ≤ 5% as determined by assay of stratified samples. High-shear wet granulation, if considered for a non-aqueous binder, requires a jacketed bowl maintained at 20–25°C to prevent heat-mediated degradation; product mass temperature exceeding 30°C on repeated batches indicates inadequate cooling and should be corrected before release.

Solutions for oral use are not marketed as stable aqueous liquids. They are dry powders reconstituted immediately before use or at pharmacy level; after reconstitution, the container is stored at 2–8°C and used within the label-specific in-use period. Injectable solutions are prepared by adding Water for Injection to the sterile powder to a final volume corresponding to the prescribed amoxicillin/clavulanate concentration; the resulting solution is administered immediately or within the product-specific compatibility window because clavulanate degradation in aqueous media is not negligible.

When Clavulanate Potassium Replaces Sulbactam or Tazobactam in Veterinary Formularies

Selection among beta-lactamase inhibitors is determined by target beta-lactamase class, partner beta-lactam compatibility, regulatory registration, and residue depletion in food-producing species. Clavulanic acid is an oxapenam that acylates class A beta-lactamases rapidly and acts as a progressive inhibitor; this makes it potent against many plasmid-mediated penicillinases found in Staphylococcus pseudintermedius, Pasteurella multocida, and Escherichia coli from veterinary isolates. Sulbactam and tazobactam are penicillanic acid sulfones that also inhibit class A enzymes but differ in chemical stability and required concentration. Sulbactam is combined with ampicillin at a ratio of 2:1 in some veterinary parenteral products, whereas clavulanate potassium is combined with amoxicillin at 4:1 or 7:1. Tazobactam is delivered with piperacillin at 8:1 in human medicine; food-producing animal residue and safety data for tazobactam are limited. All three inhibitors lack meaningful activity against many chromosomal AmpC cephalosporinases and metallo-beta-lactamases; clavulanate is not a selection agent for those enzymes. Compared with amoxicillin monotherapy, the addition of clavulanate restores susceptibility of beta-lactamase-producing strains but does not extend coverage to Pseudomonas aeruginosa or methicillin-resistant staphylococci.

In food-producing species, maximum residue limits for amoxicillin and clavulanic acid are established in Commission Regulation (EU) No 37/2010. Withdrawal periods are assigned to the finished product marketing authorization and cannot be inferred from the API specification alone. For a veterinary pharmacy or feed mill, potassium clavulanate from different suppliers should be treated as interchangeable only after validation of the same physical grade, particle size range, residual solvent profile, and packaging configuration.

Sterile Injection Grade Demands Tighter Endotoxin and Particulate Control Than Oral Premix

Sterile-grade clavulanate potassium for injection is controlled for sterility according to Ph. Eur. 2.6.1, bacterial endotoxins according to Ph. Eur. 2.6.14, and particulate matter according to Ph. Eur. 2.9.19 and 2.9.20. For small-volume parenterals, the pharmacopoeial particulate limits for the reconstituted solution are ≤ 6000 particles ≥ 10 µm and ≤ 600 particles ≥ 25 µm per container. Endotoxin limits are product-specific and are calculated from the maximum therapeutic dose rather than being an intrinsic API constant; the sterile-grade API must be accompanied by a certificate of analysis showing the measured endotoxin level and the method's sensitivity. Aseptic processing occurs in Grade A/ISO 5 filling zones with Grade B/ISO 7 background conditions; lyophilization or dry-powder filling under nitrogen is used to prevent moisture uptake. On sterile filling lines, environmental relative humidity below 30% and nitrogen flushing reduce water uptake and maintain powder flow. Reconstituted solution at 10% w/v can be filtered through 0.2 µm polyvinylidene difluoride or polyethersulfone membranes; adsorptive losses with nylon or charged membranes should be checked during filter validation. The use of siliconized stoppers should be controlled because excessive free silicone oil can generate sub-visible particles in the reconstituted injection. The container-closure system is selected for low moisture vapour transmission; butyl rubber stoppers with water content ≤ 0.5% and an aluminium cap with tamper-evident seal are typical for sterile veterinary injectables.

Bulk storage of potassium clavulanate veterinary API requires double low-density polyethylene bags inside an aluminium foil laminate with desiccant, stored at 2–8°C. The retest period is assigned from long-term stability data generated under VICH GL3 conditions; commercial veterinary-grade material often carries a retest period of 12–24 months under continuous refrigeration. At 25°C and 60% relative humidity, the powder can discolour and lose potency; a yellow or brown appearance indicates degradation and the lot should not be released. Open handling time in high-humidity areas should be less than 1 h; if relative humidity exceeds 60%, pre-drying of the processing environment and sealed transfer systems are required. Potassium clavulanate is incompatible with strongly alkaline excipients, primary amines, and reducing sugars in wet systems; these combinations accelerate beta-lactam ring opening and should be avoided unless forced degradation studies demonstrate an acceptable process window. The veterinary-grade designation does not imply a different chemical entity from human-grade material; the primary differences are documentary and supply-chain controls under VICH GL11 and VICH GL18, plus particle size and packaging specifications appropriate for veterinary dosage forms. For feed-premix operations, a non-micronized grade with controlled D90 in the 100–200 µm range is often selected to reduce dust, while direct-compression tablets typically use a micronized grade with D90 below 75 µm to improve content uniformity.